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Aptamer–nanoparticle complexes as powerful
diagnostic and therapeutic tools
Hunho Jo and Changill Ban
Correct diagnosis and successful therapy are extremely important to enjoy a healthy life when suffering from a disease.
To achieve these aims, various cutting-edge technologies have been designed and fabricated to diagnose and treat speciﬁc
diseases. Among these technologies, aptamer–nanomaterial hybrids have received considerable attention from scientists and
doctors because they have numerous advantages over other methods, such as good biocompatibility, low immunogenicity and
controllable selectivity. In particular, aptamers, oligonucleic acids or peptides that bind to a speciﬁc target molecule, are
regarded as outstanding biomolecules. In this review, several screening techniques for aptamers, also called systematic evolution
of ligands by exponential enrichment (SELEX) methods, are introduced, and diagnostic and therapeutic aptamer applications are
also presented. Furthermore, we describe diverse aptamer–nanomaterial conjugate designs and their applications for diagnosis
and therapy.
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INTRODUCTION
For several decades, nanotechnology has made remarkable
advancements in various ﬁelds, such as electricity, commu-
nication, material science, manufacturing, medical treatment
and life sciences. In particular, the convergence of biomolecules
and nanomaterials has led to a breakthrough in the
diagnosis and therapy of speciﬁc diseases, including cancers.
Biocompatible molecules, like DNA, RNA and peptides, enable
speciﬁc targeting and imaging. Moreover, the unique spectro-
scopic and thermotherapeutic properties of nanomaterials
provide superior advantages for sensing, imaging and
therapeutic applications. As shown in Figure 1, biomolecule–
nanomaterial hybrids are readily applicable to many areas.
In particular, accurate diagnosis and effective therapy have
been regarded as key factors in the medical ﬁeld. The develop-
ment of next-generation materials for successful
diagnosis and therapy has been an important research focus.
Among many substances, aptamers are recognized as
one of several remarkable agents because of their valuable
properties.1,2 Aptamers are oligonucleic acids or peptides that
have high sensitivity and robust selectivity toward several types
of target molecules, including proteins, nucleotides, peptides,
antibiotics, small molecules and cells.3 Small nucleic acid
aptamers exhibit good stability in severe conditions, and peptide
aptamers have suitable structures that interact with target
molecules. All types of aptamers contain a variable loop and
stem region that bind to a speciﬁc pocket of target molecules.
Aptamers have diverse advantages over antibodies, including
small size, easy modiﬁcation and high stability in harsh physical
and chemical environments, as well as rapid and economical
production, no batch-to-batch variation, low immunogenicity
and high ﬂexibility.4 Therefore, aptamers are regarded as
excellent substitutes for antibodies during targeting and imaging
in medical sciences, and are used in an assortment of ﬁelds.
The development of numerous nanomaterials has accelerated
advancements in diagnosis and therapy.5 A variety of nanoma-
terials, such as hydrogels, metallic nanoparticles, silica nano-
particles and carbon materials, have ideal characteristics,
including controllable physical and chemical properties, a large
surface area, robust biocompatibility and outstanding
stability.6,7 Even though nanomaterials themselves can be used
as diagnostic and therapeutic agents, they lack selective targeting
ability. Therefore, a number of aptamer–nanomaterial com-
plexes have been designed and applied to multiple areas.8–10
In this review, we focus on an overview of recent
improvements for aptamer and aptamer–nanomaterial
conjugates, as well as their applications for the diagnosis and
treatment of several diseases.
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IN VITRO SCREENING FOR APTAMERS
Target-speciﬁc aptamers are selected in vitro using a process,
called systematic evolution of ligands by exponential
enrichment (SELEX).11,12 As represented in Figure 2a, SELEX
is a repetition of four main steps: target incubation with
aptamer libraries encoding random sequences, usually 30–50
mers, and the primer-binding site; elution of bound
libraries; ampliﬁcation with polymerase chain reaction; and
single-stranded oligonucleotide separation. This procedure is
generally repeated 10–15 times, and then the selected aptamer
candidates are analyzed using cloning techniques.
To develop aptamers to recognize proteins or small mole-
cules, ﬁve types of SELEX have been generally applied. The ﬁrst
method, nitrocellulose membrane ﬁltration-based SELEX,
has been used since 1990, when it was designed by Tuerk and
Gold.12 The role of nitrocellulose membrane is to only
ﬁlter libraries that can bind to the protein based on speciﬁc
protein-binding afﬁnity. However, this method is limited to
only proteins because the nitrocellulose membrane is capable
of binding proteins. The second method is afﬁnity
chromatography-based SELEX, which uses the speciﬁc inter-
action between immobilized beads and their target molecules.
When the library is loaded onto the target-immobilized afﬁnity
column, the non-binding fraction is washed via ﬂow-through,
and a binding library is obtained.13 However, this method is
conﬁned because it requires a functional group or afﬁnity tag
on the target molecule. In addition, functionalized magnetic
bead-based SELEX has frequently been applied to discover new
aptamer candidates. Target molecules are immobilized on a
magnetic bead using a covalent bond, a speciﬁc interaction or
an electrostatic interaction between a substrate on the beads
and a speciﬁc tag on the target molecule.14 Easy and rapid
separation of the library bound to the target using an external
magnet makes this SELEX method valuable. In addition,
capillary electrophoresis-based SELEX has many advantages,
such as fast separation, high resolution, large capacity and a
small amount of samples.15 Under an electric ﬁeld, each
molecule is separated based on its charge, hydrodynamic radius
and frictional force. SELEX can be accomplished within a few
cycles using this method. Finally, SELEX is performed with a
microﬂuidic chip-based technique, which offers good selection
efﬁciency on a small scale and rapid separation via automatic
continuous-ﬂow.16 The development of microﬂuidic chip tech-
nology has the potential to enable fast and convenient SELEX.
On the other hand, aptamers for comparatively large targets,
such as cancer cells, have been identiﬁed via another method as
described in Figure 2b. Because almost all aptamers recognize
the surface biomarkers on cancers, this method is termed
‘cell-based SELEX’.17 Miscellaneous hindrances on the cell
surface, such as many non-target proteins, glycosides and
various receptors, make negative selection essential during each
cycle. Although this method requires multiple cycles, it is
signiﬁcant enough to generate aptamers identifying target cells
that do not overexpress biomarkers.
In recent years, the convergence of new technologies and
SELEX has allowed effective and economic aptamer screening.
Computational approaches have been introduced to SELEX for
the prediction and optimization of aptamer structures, binding
afﬁnity and thermodynamic characteristics.18 Several programs,
such as Resetta,19 FR3D20 and MPBind,21 have been developed
and utilized for 3D structure predictions of aptamers.22
In addition, a high-throughput sequencing technique has been
used for its high efﬁciency and extensive applicability.
High-throughput sequencing offers the complete sequence
analysis of aptamer candidates, exact quantiﬁcation, the com-
parison of binding motifs among each sequence and the
characterization of binding afﬁnities.23,24 Such substantial
advances in SELEX methods have generated noteworthy
outgrowth in the design and identiﬁcation of new aptamers,
and further modiﬁcations of SELEX have been successful in the
innovations for screening aptamers.
DIAGNOSTIC APPLICATIONS OF APTAMERS
Highly sensitive and selective aptamers have boundless
potential applications as diagnostic molecules. Diagnostic
methods are commonly categorized according to three
Figure 1 Applications of biomolecule–nanomaterial complexes.
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approaches based on detection principles. In the ﬁrst approach,
aptamers are often used to fabricate electrochemical biosensors,
which can provide an accurate, rapid and sensitive diagnosis.
Figure 3a depicts an example of electrochemical impedance
spectroscopy using aptamers.25 These electrochemical detection
methods, including cyclic voltammetry and differential pulse
voltammetry, have many advantages, such as reproducibility,
a rapid response, no probe labeling, high sensitivity and
selectivity, and no need for high-cost instrumentation.26
In addition, aptamers are valuable probes in colorimetry.
Detection in colorimetry uses color changes in some of the
particles, and a gold nanoparticle (AuNP) is one of the best
indicators for this method. Its unique characteristics, such as a
positive charge, color change according to interparticle distance
and absorption of the thiol group, enable rapid and convenient
detection. As shown in Figure 3b, the target protein can
simply be detected by the AuNP color change.27 The presence
of the target protein is conﬁrmed by the competitive binding of
the polymers. Fluorescence-based diagnosis is also used in
aptamer-based detection, which is a powerful diagnostic
and bioanalytical platform. The introduction of aptamers
to ﬂuorometry has created a synergistic effect. Recently,
Roncancio et al.28 reported a rapid and speciﬁc aptamer-
based platform for one-step cocaine detection using minimal
reagent requirements, and veriﬁed that this sensor detects
cocaine with a detection limit of 200 nM, which is 50-fold lower
than the existing limit (Figure 3c).
Moreover, it is well-known that aptamers have been
commonly utilized for other diagnostic research, such as
single-wall nanotube-based detection, surface acoustic waves,
surface plasmon resonance, micro cantilever sensing and quartz
crystal microbalance.29–32 Aptamers are novel and invaluable
next-generation targeting probes that are readily applicable to
target-speciﬁc diagnosis.
THERAPEUTIC APPLICATIONS OF APTAMERS
Some aptamers have shown high binding afﬁnity for target
molecules and an antagonistic effect on speciﬁc functions of the
Figure 2 The SELEX procedure. (a) A schematic illustration for general SELEX. It consists of four steps: incubation of target molecules
with libraries, elution of bound libraries, ampliﬁcation of the libraries and separation of the libraries for the next round. (b) A schematic
illustration of cell-based SELEX. Negative selection is required for each round.
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targets, allowing their use as probes and drugs. Dating from the
discovery of Mucugen, a vascular endothelial growth factor-
speciﬁc aptamer, in 2004 and its approval by the US Food and
Drug Administration as a new drug for treating age-related
macular degeneration, diverse aptamers have been recognized
as effective drugs for speciﬁc diseases. For example, ARC1779
(Archemix, Cambridge, MA, USA) targets activated von Will-
ebrand Factor and was designed as a drug for purpura
(Figure 4a). NOX-A12 (NOXXON Pharma, Berlin, Germany),
which targets CXCL12, was developed to treat multiple
myeloma and non-Hodgkin’s lymphoma (Figure 4b).33,34
Aptamers themselves can be valuable, useful and effective
medicines.
In addition, aptamers have been used as good drug carriers.
The intercalating properties of nucleic acid aptamers mean that
they are selective and sensitive delivery vehicles. On the basis of
the fact that doxorubicin, an anti-cancer drug, can easily
intercalate into an A10 aptamer that recognizes prostate-
speciﬁc membrane antigen (PSMA), which is overexpressed
prostate cancer, a remarkable drug carrier was designed.35 The
dual-aptamer complex is speciﬁc for both PSMA (+) and (− )
prostate cancer cells and delivers doxorubicin to the target cells
incredibly effectively and selectively. Furthermore, aptamers
can be used only as targeting molecules. For instance, the
combination of an aptamer and siRNA generates marvelous
therapeutic effects.36 Direct conjugation between the
targeting probe and siRNA provides a simple and convenient
preparation method for the drug. Countless studies have been
vigorously performed examining aptamers.
APTAMER–NANOMATERIAL COMPLEXES IN DIAGNOSIS
Quantum dots (QDs), semiconductor nanocrystals, have been
gradually used in biological and medical diagnoses owing to
their inimitable features, such as low photobleaching, high
resistance to harsh chemical degradation, high-quantum yield
and broad absorption with narrow photoluminescence
spectra.37 In particular, QDs have been regarded as excellent
Förster resonance energy transfer (FRET) donors. The basic
principle in FRET-based sensors is a target-dependent change
in ﬂuorescence signal caused by the distance between a donor
and an acceptor. Representative FRET-based sensors using
QDs are highlighted in Figure 5a.38 Good FRET properties
make aptamer-modiﬁed QDs particularly useful as probes in
diagnosis. In 2009, Zhang et al.39 designed a cocaine-speciﬁc
detection platform. The Cyanine5-modiﬁed cocaine aptamer is
hybridized to its complementary DNA, which is immobilized
on the surface of the QD, resulting in huge FRET ﬂuorescence.
The selective binding between cocaine and the cocaine aptamer
triggers a decrease in Cyanine5 ﬂuorescence. Therefore,
QD-based detection offers highly sensitive and selective
detection of target molecules.
AuNPs are one of the best sensing nanomaterials and stable
metallic nanoparticles. They retain many superior advantages
over other nanomaterials for various reasons, including their
tunable size and shape, easy and economic preparation,
size-dependent electronic and optical properties, good
biocompatibility, high intracellular stability, quenching ability
and strong interaction with thiol functional groups.40 There-
fore, studies investigating AuNP-based detection have been
Figure 3 Various applications of aptamers for detection. (a) Electrochemical impedance spectroscopic detection for MUC1. This image
was adapted from Chen et al.25 (b) Colorimetric detection. This image was adapted from Jeon et al.27 (c) Fluorescent detection.
This image was adapted from Roncancio et al.28 Apt, aptamer; ATMND, 2-amino-5,6,7-trimethyl-1,8-naphthyridine; PDDA, poly
(diallyldimethylammonium chloride); pLDH, Plasmodium lactate dehydrogenase; PoPD, poly(o-phenylenediamine); TEOS, tetraethyl
orthosilicate; Thi, thionine.
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performed for a long time. Aptamers can provide targeting
abilities to AuNPs, therefore, aptamer-modiﬁed AuNPs are
extremely useful diagnostic complexes. Target-speciﬁc AuNP
probes have been designed to have various characteristics
in countless assays, including colorimetry, ﬂuorometry,
electrochemical detection, surface plasmon resonance,
surface-enhanced Raman spectroscopy and quartz crystal
microbalance. For instance, Medley et al.41 designed a simple
and rapid detection method for cancer cells using aptamer-
modiﬁed AuNPs. Aptamer-modiﬁed AuNPs selectively bind to
target cells, and the interparticle distance decreases between the
AuNPs, which generates discernible color changes from red to
violet, leading to the straightforward detection of cells. The
superquenching capacity of AuNPs is also a unique feature.
Song et al.42 developed an ampicillin-speciﬁc AuNP sensor.
When 5’-ﬂuorescein amidite-modiﬁed aptamers are adsorbed
Figure 4 Examples of antagonistic aptamers. (a) The ARC1779 aptamer.33 ARC1779 is conjugated to a 20-kDa PEG at the 5′-terminus
(underline indicates 2′-O-methoxy nucleotides). (b) The NOX-A12 aptamer.34 iT, inverted deoxythymidine; ps, phosphorothioate linkage.
Figure 5 Diagnostic applications of biomolecule–nanomaterial complexes. (a) Three types of FRET-based detection using QDs: detection
using quencher-modiﬁed oligonucleotides, detection using ﬂuorophore-modiﬁed oligonucleotides and detection using intercalating dyes.
This image was adapted from Zhou.38 (b) Detection platform for breast cancer using dual-aptamer-modiﬁed SiNPs. HER2(+) or MUC1(+)
breast cancer cells are selectively separated using dual-aptamer-modiﬁed magnetic beads, and SiNP conjugates are incubated with the
magnetic beads-cell complexes. Breast cancer cells are quantiﬁed based on ﬂuorescence from dyes inside the SiNPs. This image was
adapted from Jo et al.45 Ex, excitation.
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to the AuNP surface via columbic interaction, quenching of the
ﬂuorophore occurs. Competitive binding of the ampicillin
aptamer to AuNPs and ampicillin enables the restoration of
ﬂuorescence from ﬂuorescein amidite, resulting in the sensitive
quantiﬁcation of ampicillin levels. In addition to these,
aptamer-AuNPs have been applied to diagnose several speciﬁc
diseases and to identify several molecules as well.
It has been known that silica nanoparticles (SiNPs) possess
facile fabrication, easy surface modiﬁcation, good biocompat-
ibility, economic synthesis, hydrophilic properties and sterically
hinder nucleases, which cleave DNA on the surface of the
particle.43 In particular, dye-doped SiNPs have received con-
siderable attention as excellent probes due to their high-
ﬂuorescence intensity, robust signal and robust resistance to
photobleaching, which hinders the ﬂuorescence signals from
almost all organic dyes. Coulombic interactions between
positively charged dye molecules and the negatively charged
silica matrix reinforces the resistance of SiNPs against photo-
bleaching. Aptamer-modiﬁed, dye-doped SiNPs are actively
utilized in many diagnosis studies. Mucin 1 (MUC1) aptamer-
immobilized, dye-entrapped SiNPs were synthesized by Cai
et al.44 and exhibited an incredibly steady ﬂuorescence signal
and high selectivity toward MUC1 (+) cell lines only. Recently,
the diagnosis of breast cancer using dual-aptamer-
functionalized SiNPs was successfully performed.45 As shown
in Figure 5b, using dye-doped SiNPs modiﬁed with a MUC1
aptamer and a human epidermal growth factor receptor 2
aptamer, various types of breast cancer cell lines overexpressing
MUC1 or human epidermal growth factor receptor 2 were
quantiﬁed. Therefore, speciﬁc aptamer-modiﬁed SiNPs can
function as beneﬁcial diagnostic tools for certain targets.
In contrast with other nanoparticles, magnetic nanoparticles
(MNPs) have a peculiar trait that improves the magnetic
resonance of adjacent water.46 In particular, the aggregation
of MNPs can cause the coupling of spin magnetic moments
and produces strong local magnetic ﬁelds, resulting in accel-
erated dephasing of water protons.47 A change in proton
relaxation times, produced by a decrease of transverse or
spin–spin relaxation times (T2), enables the detection of MNP
clusters via nuclear magnetic resonance, magnetic resonance
imaging or relaxometry. On the basis of this principle, a simple
detection method for lysozymes was developed.47 The presence
of lysozymes provokes the destruction of aggregated MNPs,
leading to an increase in T2. This sensing platform provides a
relatively high detection limit of 0.5 nM.
APTAMER–NANOMATERIAL COMPLEXES IN THERAPY
As previously described, QDs have notable features as probe
molecules. For the application of QDs to therapy, photo-
dynamic therapy (PDT) using QDs and photosensitizers has
been conducted.10 However, comparatively low apoptotic
effects and lack of targeting ability have been cited as some
drawbacks of PDT. Therefore, the direct delivery of drugs via
aptamer-modiﬁed QDs is favored rather than PDT. The
intercalating properties of several drugs into DNA or RNA
aptamers allow selective and effectual therapy. The combina-
tion of drug-intercalated aptamers and QDs facilitates simulta-
neous imaging and therapy. For example, Bagalkot et al.37
designed a theranostic complex using aptamer-modiﬁed QDs.
Figure 6 Therapeutic applications of biomolecule–nanomaterial complexes. (a) PTT using dual-aptamer-modiﬁed AuNSs. Aptamer-AuNS
agents selectively induce apoptosis by generating considerable heat (A10 aptamer for PSMA (+) cancer cells and DUP1 aptamer for
PSMA (–) cells). This image was adapted from Jo et al.51 (b) Aptamer-modiﬁed drug-encapsulated liposome. This image was adapted from
Kang et al.54 PEG, polyethylene glycol; TMR, tetramethylrhodamine.
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Doxorubicin-intercalated aptamer-QD complexes exhibited
no ﬂuorescence signal because of FRET. However, after
internalization of the complex into target cells via a speciﬁc
interaction between the aptamer and target surface proteins,
intercalated doxorubicin was released inside the cell by
lysosomes, resulting in strong ﬂuorescence from QDs and
apoptosis by doxorubicin. QD complexes can be used for the
dual functions of detection probes and delivering drugs.
Photothermal therapy (PTT) has been used in cancer
therapy because it is non-invasive compared with radiation
therapy, chemotherapy and surgery. Using near-infrared light,
photothermal agents can effectively kill target cells and
minimize unwanted injury to surrounding non-target cells.48
Of the various photothermal probes, AuNPs are one of the
most attractive particles because they enhance the damage
induced by radiation and produce high heat upon near-
infrared radiation.49 Particularly, aptamer-immobilized AuNPs
are noteworthy in targeted therapy. For instance, Wang et al.50
designed a smart complex that can selectively and sensitively
kill target cells via PTT, as well as via PDT. As aptamer–
photosensitizer-gold nanorods (rod-shaped AuNPs) can
target-speciﬁc cells using aptamers, and can also destroy cells
using PTT and PDT, ultra-efﬁcient therapy is achievable.
Furthermore, multiple aptamer-modiﬁed gold nanostars
(AuNSs) were also developed, as represented in Figure 6a.51
Newly synthesized AuNSs complexes showed high selectivity
toward PSMA(+) and PSMA(–) cells, and extremely high
efﬁciency for PTT using an 808-nm laser under an irradiance
of 0.3W cm−2. In addition, AuNPs can be used as drug-
delivery vehicle, as mentioned previously. Luo et al.52 fabricated
a drug-delivery conjugate based on AuNPs. A drug intercalated
in the aptamers can be released by irradiation, leading to
selective and effective therapy.
It is widely known that liposomes encapsulate not only
hydrophilic therapeutic drugs inside the aqueous center,
but also hydrophobic therapeutic drugs within the bilayer
membrane.53 Studies on liposome therapy have been
performed for a long time, and a few liposome-based drugs
have already been approved for clinical use. The immobiliza-
tion of aptamers onto the liposome surface can assign targeting
capabilities to the liposome. In 2010, Kang et al.54 fabricated
sgc8 aptamer-modiﬁed, liposome-targeting CEM-CCRF cells.
Aptamers were immobilized on a dextran-encapsulated
PEG-liposome, and then applied to CEM-CCRF cells, resulting
in highly effective and selective apoptosis of target cells
(Figure 6b).
In addition, micelles have also been frequently utilized in
therapeutic applications and are a cluster of surfactants such as
soap, phospholipids and fatty acids. In an aqueous solution, the
hydrophobic tails aggregate in the center of a micelle, and the
polar heads are oriented toward the outside. Therefore,
targeting molecule-modiﬁed micelles can selectively deliver
hydrophobic anti-cancer drugs analogous to liposome-based
carriers. Mu et al.55 designed the FB4 APP (aptamer-modiﬁed
PEG-polylactic acid micelles) that targets the TfR on endothe-
lial cells in the brain. For therapy, ﬂurbiprofen, a potential
Alzheimer’s disease drug, was encapsulated inside APP mole-
cules, and the drug complexes were applied to target cells. The
micelle-based complex showed increased binding efﬁciency in
the target brain cells.
Of the several types of magnetic particles, superparamagnetic
iron oxide nanoparticles (SPIONs) possess distinct character-
istics, including good dispersibility, biocompatibility and anti-
biofouling properties that inhibit the adsorption of plasma
proteins or cells onto their surface.56 They have been used as
magnetic resonance contrast agents or magnetic ﬁeld-guided
drug-delivery vehicles. For the application of these molecules to
therapy, drug-intercalated aptamers are immobilized on the
surface of SPION in a similar manner. Thermally cross-linked
SPION was modiﬁed with PSMA (+) and (− ) aptamers
and doxorubicin.35 According to the results, this complex
can selectively and effectively release the drug to prostate
cancer cells.
CONCLUDING REMARKS
In this review, we have discussed a range of applications for
aptamers and aptamer–nanomaterial complexes in diagnosis
and therapy. The merging of aptamers and nanomaterials can
provide a highly sensitive biosensing system, target-speciﬁc
imaging and efﬁcient therapy. Outstanding improvements
in nanotechnology and biotechnology have generated
innumerably valuable outcomes and resulted in current novel
innovations; however, some challenges remain. In the case of
aptamers, there are some limitations, such as a relatively short
half-life, low speciﬁcity for target molecules, and exposure
to serum degradation. There are also challenges with nanoma-
terials, including the short half-life of particles in circulation,
low permeability and difﬁculties in large-scale synthesis.
Nevertheless, aptamer–nanomaterial complexes are fascinating
and have promising properties; remarkable techniques
have been applied to overcome the existing weaknesses.
Fervent attempts to develop innovative and creative aptamer–
nanomaterial conjugates will continue, and these complexes
will be recognized as novel platforms in many ﬁelds, including
medical diagnostics and therapeutics.
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